Becton, Dickinson and Company (NYSE:BDX)‘s stock had its “sector perform” rating reiterated by analysts at Royal Bank Of Canada in a research note issued on Friday, Marketbeat.com reports. They presently have a $230.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $210.00. Royal Bank Of Canada’s target price indicates a potential upside of 2.49% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on BDX. Cowen and Company reissued an “outperform” rating and issued a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Monday, July 10th. BidaskClub raised shares of Becton, Dickinson and from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a research report on Monday, July 17th. Bank of America Corporation reissued a “buy” rating and issued a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Becton, Dickinson and has a consensus rating of “Buy” and an average price target of $211.94.

Shares of Becton, Dickinson and (NYSE BDX) traded up $16.35 during trading on Friday, hitting $224.41. 1,405,516 shares of the stock were exchanged, compared to its average volume of 1,325,794. The company has a market capitalization of $50.98 billion, a P/E ratio of 23.61 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. Becton, Dickinson and’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.12 earnings per share. equities analysts forecast that Becton, Dickinson and will post 10.65 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/03/royal-bank-of-canada-raises-becton-dickinson-and-company-bdx-price-target-to-230-00.html.

In other Becton, Dickinson and news, insider Ellen R. Strahlman sold 9,283 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the transaction, the insider now owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. In the last three months, insiders have sold 75,904 shares of company stock valued at $15,242,688. Insiders own 1.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its stake in Becton, Dickinson and by 8.5% during the second quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after acquiring an additional 1,353,780 shares in the last quarter. BlackRock Inc. increased its stake in shares of Becton, Dickinson and by 2,427.8% in the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after buying an additional 15,887,611 shares during the period. State Street Corp increased its stake in shares of Becton, Dickinson and by 3.5% in the second quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock valued at $2,003,834,000 after buying an additional 342,873 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Becton, Dickinson and by 6.5% in the first quarter. JPMorgan Chase & Co. now owns 3,967,843 shares of the medical instruments supplier’s stock valued at $727,863,000 after buying an additional 242,081 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Becton, Dickinson and by 4.0% in the second quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock valued at $549,028,000 after buying an additional 106,966 shares during the period. 86.70% of the stock is owned by hedge funds and other institutional investors.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.